Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Nanoform Finland

0.69 EUR

-1.57 %

3,695 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.57 %
-18.87 %
-41.30 %
-27.58 %
-21.82 %
-34.10 %
-67.24 %
-91.35 %
-86.38 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
58.94M EUR
Turnover
61.09K EUR
Revenue
3.55M
EBIT %
-521.09 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.4
2026

General meeting '26

19.5
2026

Interim report Q1'26

20.8
2026

Interim report Q2'26

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – David Rowe

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Christian Jones

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Antonio Da Silva

Nanoform Finland
Regulatory press release3/2/2026, 2:00 PM

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release3/2/2026, 6:10 AM

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees

Nanoform Finland
Regulatory press release2/26/2026, 6:10 AM

Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe

Nanoform Finland
Press release2/13/2026, 9:00 AM

Invitation to Nanoform’s Q4 and FY2025 Report Presentation

Nanoform Finland
Press release2/12/2026, 6:00 AM

Nanoform - Subcutaneously administered Nanotrastuzumab matches performance of Herceptin HYLECTA in minipig study

Nanoform Finland
Regulatory press release2/5/2026, 6:05 AM

Nanoform Finland Plc’s change negotiations have ended

Nanoform Finland
Regulatory press release1/29/2026, 5:00 PM

Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Nanoform Finland
Regulatory press release1/7/2026, 6:05 AM

Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030

Nanoform Finland
Press release12/30/2025, 9:00 AM

Nanoform financial calendar for 2026

Nanoform Finland
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/16/2025, 5:00 AM

Inside information: Nanoform announces new midterm business targets for 2030

Nanoform Finland
Press release11/13/2025, 6:00 AM

Nanoform Capital Markets Day December 16th, 2025

Nanoform Finland
Regulatory press release11/12/2025, 6:10 AM

Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set

Nanoform Finland
Regulatory press release11/11/2025, 6:00 AM

Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License

Nanoform Finland
Press release10/29/2025, 9:00 AM

Invitation to Nanoform’s Q3 2025 Report Presentation

Nanoform Finland
Forum discussions
This company is tricky to evaluate in the short term, as such a large portion of its potential depends on projects conducted with customers, about which not much can be disclosed externally yet for understandable reasons. If information were available regarding, for example, the ...
3/1/2026, 5:39 PM
by jerej
16
I plotted these Handelsbanken holdings. Sales have now averaged 500k per month. If Handelsbanken intends to sell off its entire position, and those sales continue at the same pace as they have so far, the selling pressure will likely continue until roughly next summer. There hasn...
3/4/2026, 1:39 PM
by jerej
10
I listened to that webcast yesterday. I’ll share my thoughts over the weekend. According to the CEO, the cash burn estimate for this year (approx. -€10M) does not include milestone payments. Management likely doesn’t want to forecast them for this year as their timing is probably...
2/27/2026, 4:08 PM
by jerej
8
This sums up the case quite well at the moment. Personally, I’m still quite optimistic about this. At least so far, everything seems to be progressing, though maybe two years behind what was originally thought. Perhaps many others have invested here with a shorter-term view, but ...
3/2/2026, 1:30 PM
by jerej
6
My guess is that partnering negotiations are still ongoing for some reason. These haven’t been updated recently, but here is the 2025 H1 update on the situation at that time. At that stage, the only market for which an agreement had already been signed was Germany. edit: I dug a ...
11 hours ago
by jerej
5
260,000 shares decreased in February at Handelsbanken. -30,000 shares for HÆGGSTRÖM ALBERT ALEXANDER. I wonder if there were some transfers since no notification has been issued.
3/7/2026, 1:00 AM
by Latupuikko
3
Thank you Jerej for your comprehensive and thoughtfully reflective response. I need to read this carefully at a suitable moment, and also listen to the webcast while following the slides. There is information there, after all. The situation would be so much nicer if the cash position...
3/1/2026, 9:39 PM
by JusaVaan
3
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.